Jagsonpal Pharmaceuticals Limited — PPTs, 03-11-2025: Investor Presentation

Jagsonpal Pharma posted strong H1FY26 results: revenue jumped 10.2% YoY to ₹150.1 Cr, and profit (PAT) surged 39.2% to ₹23.4 Cr. Q2FY26 revenue was steady at ₹74.5 Cr, with PAT up 9.7% to ₹12.6 Cr, despite a temporary slowdown from GST 2.0 transition.

The company follows an asset-light model, focusing on innovation with 4-6 new product launches annually, empowering its sales team, and strategic acquisitions to expand its portfolio in Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Recent developments include strengthening the leadership team with a new COO and CFO. Jagsonpal maintains a healthy cash balance of ₹160.4 Cr. Management expects continued growth, driven by strong fundamentals and operational excellence.